Project Grant R43AI191860
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $314K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Trellis Bioscience, Inc. $999,759 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to complete clinical trial preparation of TRL3D3, a human monoclonal antibody targeting respiratory syncytial virus. TRL3D3 is directed against the RSV G protein, which serves as the key attachment factor for infecting airway epithelial cells and modulates host immune response contributing to pathological...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $853,847 to Massachusetts General Hospital on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of virologic and immunologic features of RSV immunoprophylaxis and escape. The recipient will sequence the genomes of approximately 3,000 biobanked and prospectively collected respiratory syncytial virus...
- The National Institute of Allergy and Infectious Diseases awarded University of Kansas Medical Center Research Institute, Inc. $193,750 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on the role of cell-surface glycoRNAs in respiratory syncytial virus infection. The research will define the sequences and secondary structures of glycoRNAs that scaffold nucleolin, an RNA-binding protein and critical RSV entry receptor, on...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $364,484 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, to support research on soluble guanylate cyclase (SGC) pathway activation as a novel bronchodilation strategy for respiratory syncytial virus (RSV) bronchiolitis in pediatric populations. The research project, with an ultimate completion date of June 30, 2027,...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $1.62 million on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize novel inhibitors targeting the polymerase and endonuclease activities of the L protein of human pathogenic mammarenaviruses. The recipient will conduct biochemical, cell-based functional, structural, and viral genetics studies to define the mechanisms of action of two...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $618,650 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on ZBP1 signaling in respiratory syncytial virus (RSV) triggered host defense and pathogenesis. The research examines how RSV activates the immune sensor protein ZBP1, which triggers necroptosis in infected stromal cells and pyroptosis in myeloid cells. The project investigates...
- The National Institute of Allergy and Infectious Diseases awarded Oklahoma State University $403,320 on February 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a novel live-attenuated respiratory syncytial virus (RSV) vaccine for neonatal infants. The project addresses RSV as the largest viral cause of pediatric bronchiolitis and pneumonia, responsible for more than 100,000 deaths in children worldwide. Although the FDA recently approved...
- The National Institute of Allergy and Infectious Diseases awarded Alveolus Bio, Inc. $301,768 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop RSB11, a Lactobacillus-based nasal spray therapeutic for chronic rhinosinusitis. RSB11 employs advanced particle engineering and spray drying technologies to optimize nasal delivery and bacterial viability. The award funds two research aims. Aim 1 involves comprehensive in vitro studies using...
- The National Institute of Allergy and Infectious Diseases awarded Mapp Biopharmaceutical, Inc., $1.986 million in project grant funding on September 24, 2025, to develop MBP002, a fully human monoclonal antibody product for respiratory syncytial virus (RSV) immunoprophylaxis in neonates and infants. The award operates under the Allergy and Infectious Diseases Research program (CFDA 93.855). MBP002 is formulated as a two-antibody cocktail administered in a single dose per RSV season, designed...